Impact of the COVID-19 Pandemic on Acute Ischemic Stroke Presentation, Treatment, and Outcomes
Table 3
Comparisons within 2020 time periods.
Pre-COVID
Peak-COVID
Post-COVID
value
199
100
141
Age
18–39
0 (0)
2 (2.0)
4 (2.8)
40–59
39 (19.6)
20 (20.0)
24 (24.1)
60–79
88 (44.4)
46 (46.0)
57 (40.4)
80+
72 (36.2)
32 (32.0)
46 (32.6)
Sex
Female
106 (53.3)
44 (44.0)
69 (48.9)
Male
93 (46.7)
56 (56.0
72 (51.1)
NIHSSS
Unknown
28 (14.1)
13 (13.0)
16 (11.4)
0–9
115 (57.8)
56 (56.0)
68 (48.2)
10+
56 (28.1)
31 (31.0)
57 (40.4)
Mode of arrival
EMS
60 (30.2)
34 (34.0)
50 (35.5)
Others/Unknown
30 (15.1)
13 (13.0)
13 (9.2)
Private
48 (24.1)
31 (31.0)
38 (27.0)
Transfer
61 (30.6)
22 (22.0)
40 (28.3)
LKW to arrival
Unknown
40 (20.1)
28 (28.0)
35 (24.8)
0–4.5
50 (25.1)
22 (22.0)
38 (27.0)
4.5–6
8 (4.0)
8 (8.0)
6 (4.3)
6–24
48 (24.1)
24 (24.0)
46 (32.6)
>24
53 (26.6)
98 (98.0)
16 (11.4)
EVT
Not treated
183 (92.0)
98 (98.0)
125 (88.7)
EVT
16 (8.0)
2 (2.0)
16 (11.4)
tPA
Not treated
191 (96.0)
98 (98.0)
130 (92.2)
IVtPA
8 (4.0)
2 (2.0)
11 (7.8)
Discharge location
Expired
24 (12.1)
12 (12.0)
18 (12.8)
Home
80 (40.2)
44 (44.0)
58 (41.1)
Others
95 (47.7)
44 (44.0)
65 (46.1)
LOS
0–7
102 (51.3)
65 (65.0)
96 (68.1)
8+
97 (48.7)
35 (35.0)
45 (31.9)
NIHSS: National Institute of Health Stroke Scale; LKW: last known well; EMS: emergency medical services; EVT: endovascular therapy; IVtPA: intravenous tissue plasminogen activator; LOS: length of stay. Statistical significance.
